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Abstract
Introduction: Tumor necrosis factor (TNF) is a cytokine able to exert anti-tumor activity in various models and modes of
applications. However, the exact mechanism mediating the in vivo anti-tumor effect of TNF has not yet been clarified. 
Materials and Methods: The effects of intratumoral injection of rat TNF into hamsters bearing Bomirski Ab amelanotic
melanoma, a fast growing tumor of high metastatic potential, were tested. Subcutaneous injections of the anti-angiogenic
compound TNP-470 allowed analysis of its influence on the effects of TNF administration.
Results: TNF application resulted in a significant inhibition of tumor growth and changes in metastasis pattern. Accelerated
hemorrhagic necrosis was also observed, indicating the effect of the cytokine on tumor vessels. Moreover, the synergistic
anti-tumor effect of TNF and anti-angiogenic agent TNP-470 suggested a cooperative activity of both substances on tumor
vasculature. Microscopically, the effect of TNF injections was expressed by an increase in the amount of tumor cells with
nuclear pyknosis and karryorrhexis. In vitro assays indicated a direct cytotoxic effect of TNF against Ab melanoma cells, most
probably as an outcome of apoptosis. Intratumoral application of TNF also caused some modulation of cytokine response in
melanoma-bearing hamsters as evidenced by increased levels of IL-6 in blood serum.
Conclusions: This study established Bomirski Ab melanoma as a useful model for complex analysis of the anti-tumor activity
of TNF. 
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INTRODUCTION
Tumor necrosis factor (TNF, TNF-α, cachectin) is
a multifunctional cytokine produced mainly by activated
macrophages and/or monocytes. It can also be produced
by some tumor cell lines [35]. TNF occurs as a 26-kDa
transmembrane precursor form and as a 17-kDa soluble
mature form, which appears mainly as a homotrimer
[62]. Mature TNF displays a high degree of homology in
mammals [41, 72] and therefore its biological activity
has limited species specificity [58].
TNF was firstly reported as a macrophage-derived
serum factor that caused hemorrhagic necrosis of
tumors [12]. Today, TNF is well-known as having a wide
range of biological activities both in vitro and in vivo
[40]; for example, it affects the proliferation of normal
cells, takes part in homeostasis regulation, inflammato-
ry, immunoregulatory, and antiviral responses, and
plays an important role in septic shock [2, 61, 63, 68].
TNF also exerts some cytotoxic and cytostatic effect on
numerous tumor cell lines in vitro [51] and exhibits anti-
-tumor activity in some tumor models in vivo [20, 53].
Systemic treatment with TNF, however, is associated
with severe side-effects, and this limits the clinical use of
the cytokine in the therapy of melanomas mainly to the
isolated limb perfusion regimen [18]. 
The exact mechanism mediating the in vivo anti-
-tumor effect of TNF has not been yet fully clarified.
There are at least three possible ways in which TNF can
exert anti-tumor activity: by direct cytostatic or cytotox-ic action on tumor cells, by its effect as a regulatory
mediator of the host-mediated immunological response
in neoplasia, and by augmenting hemorrhagic necrosis
within a tumor by affecting its vasculature. Further-
more, cell sensitivity to the growth-inhibiting effect of
TNF is influenced by other cytokines, hormones, growth
factors, and drugs [2, 32, 64].
In order to analyze the mechanism of TNF action in
melanoma, we decided to analyze the effect of TNF on
Bomirski (Ab) amelanotic melanoma in the hamster. It
is a transplantable, highly stable tumor with a behavior
resembling the clinical situation. Ab melanoma is a rel-
atively immunogenic, quickly growing tumor with
a mean survival time of tumor-bearing animals of about
25 days. The primary tumor metastasizes mostly to the
kidneys and lymph nodes [10, 11]. Ab melanoma is also
sensitive to the cytotoxic effect of natural killer (NK)
cells at the metastasis formation stage [9] and the
tumor’s presence alone can increase the cytotoxic activ-
ity of macrophages and NO release [34]. However,
tumor growth can also induce immunosuppression in
tumor-bearing animals [45]. Therefore, in the Ab
melanoma model one may possibly analyze all the
aspects of TNF’s effect on tumor growth and metastasis.
MATERIALS AND METHODS
Materials
Recombinant rat TNF with a specific activity of
1.1×108 U/mg of protein was prepared in our laborato-
ry. The complementary DNA of rat TNF gene was
cloned into the pET16b vector (Novagen, USA) under
a lactose operon and expressed in the E. coli
BL21(DE3) strain. The expressed protein was purified
to homogeneity by a combination of chromatographic
procedures and the use of Polymyxin B (Sigma, USA) as
described in our earlier publication [33]. The endotoxin
content was measured by the Limulus amebocyte assay
and was found to be <60 ng/ml. Human recombinant
TNF was the generous gift of Dr. Schwendemann
(BASF Knoll AG, Germany). Hemisynthetic analogue
of fumagillin TNP-470 (AGM-1740) was the generous
gift of Takeda Chemical Industries Ltd., Japan. 
Administration of rat TNF
to hamsters bearing Ab melanoma
Four-month-old random-bred male Syrian (golden)
hamsters were used in the study. They were purchased
from the animal colony of the Silesian Medical
University (Katowice, Poland) and maintained at our
animal facility on a standard diet and water ad libitum.
The tumor was an amelanotic variant of Bomirski
melanoma, which was maintained by serial passage in
hamsters using the suspension method of transplanta-
tion [11]. A suspension of melanoma cells from the pri-
mary tumor was injected subcutaneously into the right
flank of the animal. After 5–8 days, a palpable tumor
was observed. Rat TNF was then injected intratumoral-
ly for a period of 10 days, once a day between 10 and 12
a.m. at a dose of 20 or 40 µg in an injection volume of
0.25 ml. Control tumor-bearing animals received injec-
tions of 0.25 ml of vehicle (20 mM Tris, 300 mM NaCl,
0.1% BSA, pH 8.0). Three dimensions of a tumor were
measured daily and its surface and volume were then
calculated. The animals were killed by decapitation on
days 21–23 after the tumor injection at the onset of
irrevocable cachexia. After decapitation, autopsy was
done and the tumors were excised and weighed. Only
the animals used for the preparation of histological
slides and the isolation of blood serum, splenocytes, and
peritoneal macrophages were killed after three days of
TNF treatment and/or 8–11 days of TNP-470 treatment
(8–11 days after tumor implantation). 
All animal experiments were performed with per-
mission of the Local Ethics Commission, Medical
University of Gdañsk, and in agreement with the guide-
lines thereof. 
Administration of TNP-470 
to hamsters bearing Ab melanoma
Ab amelanotic melanoma implantation was conduct-
ed as described above. From the day of tumor implanta-
tion on, TNP-470 was daily injected subcutaneously into
the flank opposite the tumor at a dose of 30 mg/kg of
body mass and in avolume of 0.5 ml. Control tumor-bear-
ing animals were given injections for 21 days of 0.5 ml of
vehicle (0.1% ethanol solution with 5% of Arabic gum).
The animals were subsequently killed as described above.
Preparation of microscope slides of tumors
Microscope slides were prepared from tumors 8–11
days after tumor implantation. Excised tumor sections
were fixed in formalin and embedded in paraffin.
Paraffin sections were stained with hematoxylin and
eosin using the method of May-Grünewald-Giemsa.
Preparation of the cell isolates
Splenocytes or tumor cells were isolated by pressing
spleens or primary tumors through a 0.1-mm-pore
strainer and then purified by centrifugation on Ficoll
400 (Pharmacia, Sweden) and Uropolin (Polfa, Poland)
gradient. Contaminating erythrocytes were hemolysed
with cold distilled water and purified cells were washed
with phosphate buffered saline (PBS).
Peritoneal macrophages were harvested from ani-
mals injected i.p. with 10 ml of thioglycolate broth
(2.98% solution; Difco, USA) 5 days earlier. Cells were
washed out from the peritoneal cavity with PBS, filtered
through a 0.05-mm-pore strainer and purified by cen-
trifugation on Dextran (MW=70.000) and Uropolin
(Polfa, Poland) gradient.
Splenocytes and thioglycolate-elicited peritoneal
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tumor-bearing animals, and tumor-bearing animals
injected intratumorally with TNF at a dose of 20 µg for
three days from the moment the tumor had become pal-
pable and 8–11 days from tumor implantation. 
Assay for the cytotoxic activity of TNF 
on Ab cells in primary culture
The cytotoxic activity of TNF was measured with the
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay [44]. Isolated tumor cells were
seeded in a 96-well plate at a density of 5×104 cells per
well with serial dilutions of rat TNF in 0.1 ml of culture
medium consisting of F-10 (Biomed, Poland), 10% fetal
bovine serum (FBS; Gibco, USA), 100 U/ml penicillin,
and 0.1 mg/ml streptomycin and incubated at 37oC in
5% CO2. After 45 h of incubation, 20 µl of a 5 mg/ml
MTT solution (Sigma, USA) was added to each well and
incubation was continued for 3 h at 37oC with 5% CO2
to allow MTT metabolization. The resultant formazan
crystals were dissolved by adding 100 µl of isopropyl
alcohol with 0.4 N HCl per well [44]. The optical densi-
ty at 630 nm was measured using a Multiscan
MCC/340P microplate reader (Labsystems, Finland).
The optical density of wells containing cells cultured
without TNF was assumed to be 100% of cell viability.
Assay for the cytotoxic activity of TNF 
on tumor cells in primary culture enriched 
in splenocytes or peritoneal macrophages
Splenocytes and peritoneal macrophages were isolat-
ed from healthy and tumor-bearing animals as above.
Splenocytes were either irradiated (3600 Gy, 7 min) or
not irradiated. Purified tumor cells were seeded into
a 96-well plate at a density of 5×104 cells/well, macro-
phages at 1×105 cells/well, and splenocytes at 2.5×105
cells/well with a serial dilution of rat TNF in 0.1 ml of
culture medium with the composition as above at 37oC in
5% CO2. The TNF effect on tumor cells in co-cultures
with the effector cells was measured by the MTT assay or
by the /methyl-3H/-thymidine incorporation assay. The
MTT assay [44] was performed as described above. The
optical density of wells containing cells cultured without
TNF was assumed to be 100% of cell viability, separate-
ly for each co-culture of cells. For the isotopic method,
the co-cultures were pulse-labeled with /methyl-3H/-
-thymidine (1 µCi/well; Polatom, Poland) for 6 h before
harvest with an automatic cell harvester (Skatron
Instruments, USA) 45 h after the culture initiation.
Radioactivity of the samples was measured with an
LS60001C liquid scintillation counter (Beckman, USA). 
Assay for the NK cytotoxic activity of splenocytes 
and the natural cytotoxicity of macrophages in vivo
Splenocytes and peritoneal macrophages were iso-
lated from healthy animals, tumor-bearing animals, and
tumor-bearing animals treated with TNF as described
above. The NK cytotoxic activity of splenocytes was
measured by the 51Cr release assay on K562 target cells.
Target cells were labeled for one hour by 0.1 mCi of
Na2
51CrO4 (Polatom, Poland) for 2×107 cells in 0.1 ml of
RPMI (Biomed, Poland) with 20% FBS and then seed-
ed in a 96-well plate at a density of 2×104 cells/well. The
splenocytes were added at the effector:target ratios of
5:1, 10:1, and 25:1 for splenocytes from the healthy ani-
mals and 25:1 for the other splenocytes. The cells were
incubated for 4 h in 0.2 ml of culture medium consisting
of RPMI, 10% FBS, β-merkaptoethanol, 100 U/ml peni-
cillin, and 0.1 mg/ml streptomycin. The activity of
released isotope in culture medium was measured with
a gamma counter (Minigamma Spline, Germany). The
percentage of specific 51Cr release was calculated as: 
experimental release 
% of specific – spontaneous release      
× 100 51Cr release  =
total release 
– spontaneous release
Experimental release is the radioactivity released in
wells containing activated effector cells and target cells;
spontaneous release the radioactivity released from tar-
get cells incubated in the medium alone, and total
release the radioactivity from target cells lysed with 75%
acetic acid. The spontaneous release was less than 5% of
the total release. Each test group was assayed in tripli-
cate or quadruplicate and all the experiments were
repeated at least 3 times.
The cytotoxic activity of macrophages in vitro was
measured by the /methyl-3H/-thymidine incorporation
assay on K562 target cells. Target cells were seeded in
a 96-well plate at a density of 5×104  cells/well.
Macrophages were added at the effector:target ratios of
0.1:1, 0.5:1, and 1:1 for macrophages from the healthy
animals and 1:1 for the other macrophages. Cells in 0.1
ml of culture medium consisting of RPMI, 10% FBS,
5×10–5 M β-merkaptoethanol, 100 U/ml penicillin, and
0.1 mg/ml streptomycin were pulse-labeled with
/methyl-3H/-thymidine (1 µCi/well) for 4 h before har-
vest with an automatic cell 20 h after culture initiation.
The radioactivity of the samples was measured with an
LS60001C liquid scintillation counter. 
Quantitative determination of cytokine concentrations
in blood serum samples
Blood samples were isolated under general anesthe-
sia from the hearts of tumor-bearing animals 8–11 days
after tumor implantation and three days of TNF or
vehicle treatment from the moment the tumor had
become palpable or from healthy animals of the same
age. The animals were then killed by decapitation.
Serum was obtained by blood coagulation and centrifu-
gation.
The TNF concentration was measured by a standard
cytotoxic assay coupled with the neutral red uptake assay
[70]. One day before the assay, TNF-sensitive mouse A9
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sity of 3×104 cells/well in 0.1 ml of culture medium con-
sisting of DMEM (Biomed, Poland), 10% FBS, 4 mM 
L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml strepto-
mycin. The cells were incubated for 9 h with blood serum
samples at a dilution of 1:10 in the culture medium with
cycloheximide (0.25 mg/ml). Human recombinant TNF
dilutions were used for plotting the standard curve.
Interleukin (IL)-6 activity was measured by a prolif-
erative assay coupled with the /methyl-3H/-thymidine
incorporation assay. Mouse B9 myeloma cells were
seeded in a 96-well plate at a density of 1×104 cells per
well in 0.1 ml of culture medium consisting of RPMI,
10% FBS, 5×10–5 M β-merkaptoethanol, 100 U/ml
penicillin, and 0.1 mg/ml streptomycin. The cells were
incubated for 68 h with a blood serum sample at a dilu-
tion of 1:10 or a serially diluted supernatant from the
murine splenocyte culture (obtained from Dr. M.
Cichorek, Laboratory of Embryogenesis, Medical
University of Gdañsk). This supernatant was prepared
by 48 h of culture in RPMI with 5% FBS and 10 µg/ml
of Concanavalin A and then titrated against recombinant
IL-6. After incubation the cells were pulse-labeled with
/methyl-3H/-thymidine (1 µCi/well) for 4 h before har-
vest with an automatic cell harvester. The radioactivity
of the samples was measured with an LS60001C liquid
scintillation counter.
Statistical analysis
Statistical analysis for the tumor growth rate was
performed with a combination of Morgan test and
Student’s t-test distribution analysis. Statistical analysis
for the rate of appearance of advanced hemorrhagic
necrosis was performed with the Fisher test using the
Statistica program (StatSoft Inc., USA).
RESULTS
The effect of rat TNF on the growth 
of hamster Ab melanoma
In order to analyze the effect of rat TNF on Ab
melanoma growth in vivo, rat TNF was applied intratu-
morally for a period of 10 days from the moment the
tumor had become palpable. The rate of tumor growth
in vehicle- and TNF-treated tumor-bearing hamsters is
shown in Fig. 1A. In vehicle-treated tumor-bearers, Ab
melanoma developed rapidly. There was also no differ-
ence between the results from untreated tumor-bearers,
vehicle-treated, and animals treated with inactivated
TNF (incubated for 30 min at 100oC, the data not
shown). In TNF-treated animals, tumor growth was par-
tially inhibited. The differences in tumor volume
between control and TNF-treated animals were statisti-
cally significant from the 4th day of TNF treatment. The
differences lasted till the day of the death of the animals
and were reflected in the differences in tumor mass as
shown in Fig. 1B. The inhibitory effect of TNF on tumor
growth was dose dependent since the effect of 40 µg
TNF per day was significantly stronger than the effect of
the 20-µg dose on the 10th day of tumor treatment.
There was also one case of complete regression of
tumor induced by treatment with a 40-µg dose of TNF.
Therefore, TNF intratumoral injections inhibited Ab
melanoma growth in a dose-dependent manner.
The effect of TNF treatment on systemic metastasis 
of Ab melanoma and survival of tumor-bearing animals
Ab melanoma metastasizes mostly to the kidneys
and lymph nodes. Intratumoral application of TNF
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Fig. 1. Dose-dependent inhibitory effect of rat TNF on Ab
melanoma growth in vivo. TNF at a dose of 20 or 40 µg per injection
was applied intratumorally. Control animals were injected with
vehicle (see Materials and Methods). Graph A represents average
measurements of the tumor volume during experiments. Graph
B represents average tumor mass on the day of autopsy. Mean devi-
ations are indicated. Results were obtained from 18 control animals
and from 13 or 5 animals injected with TNF in the dose of 20 (TNF
(20)) or 40 µg (TNF (40)), respectively (from 5 independent exper-
iments). The differences between the growth rates of the tumors of
control animals and animals injected with TNF were statistically sig-
nificant from day 4 of treatment (*) and between two doses of TNF
at day 10 (**). The differences were also significant for tumor mass
between control and TNF-treated animals (*) on the day of autopsy
(p<0.05). DTI – day of tumor implantation, DA – day of autopsy.changed the pattern of systemic metastasis. The most
evident effect of TNF treatment was a lower incidence
of kidney metastases (Table 1). This effect was dose
dependent and statistically significant, as shown by the
non-parametric Fisher test at a p value of less than 0.02.
TNF also significantly augmented the frequency of
metastasis to the peritoneal cavity and the lungs in the
animals treated with TNF at a dose of 40 µg/day in com-
parison with the control animals (Table 1). Notwith-
standing the effect on Ab melanoma growth and metas-
tasis, the therapy with TNF did not significantly affect
animal survival. TNF treatment also caused no weight
reduction compared with the control tumor-bearing ani-
mals (data not shown).
The effect of TNF treatment 
on tumor hemorrhagic necrosis
The effect of TNF on Ab melanoma vasculature was
analyzed mostly by its effect on hemorrhagic necrosis of
tumors. Advanced hemorrhagic necrosis, manifesting as
a tumor perforation and a clot on its surface, was absent
in some of the control animals, but all of the TNF-treat-
ed animals showed its signs. As seen in Fig. 2, intratu-
morally injected TNF also had a statistically significant
acceleratory effect on the appearance of advanced
tumor hemorrhagic necrosis during the period of TNF
treatment compared with the control animals.
Histological examination of tumors treated 
with TNF and the angiogenesis inhibitor TNP-470
To analyze the effect of TNF on tumor blood vessels
in the Ab melanoma model, we decided to use a known
angiogenesis inhibitor, TNP-470, for comparison and as
a possible synergistic agent. TNP-470 is a hemisynthetic
fumagillin analogue which not only inhibits angiogene-
sis [7, 29], also in Ab melanoma [46, 47], but has a cyto-
static and cytotoxic effect on endothelial cells [27, 73].
Histological examination of tumors was done at the
early stage of tumor growth. Even a short, 3-day period
of TNF injections at a dose of 20 µg/day was sufficient
to cause changes in tumor tissues. These changes were
expressed as areas of fibrosis and accumulations of
tumor cells with nuclear pyknosis and karyorrhexis (Fig.
3B). There were no such changes in the control tumors
(Fig. 3A), which were injected intratumorally with
a vehicle in the same volume as the TNF preparation.
This seems to indicate that the changes were not a result
of mechanical damage. TNF treatment did not cause
visible injury to the tumor vessels. Such injury and ery-
throcyte extravasation could be seen on histological sec-
tions of tumors treated with the hemisynthetic inhibitor
of angiogenesis TNP-470 (Fig. 3C). Furthermore, this
effect of TNP-470 on tumor vasculature was augmented
by TNF in the combined treatment (Fig. 3D).
The mechanism of the TNF effect on tumor cells in vitro
In order to analyze the possible mechanism of TNF
action on tumor cells in Ab melanoma, first the effect of
TNF on the viability of tumor cells in primary culture
was measured. TNF displayed a dose-dependent cyto-
toxic effect on Ab tumor cells in primary culture as
shown in Fig. 4. However, apart from amelanoma cells
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Table 1. Effect of TNF application on systemic metastasis of Ab melanoma
Percentage of animals with tumor metastases present in the indicated organs
kidneys liver mediastinum armpit lungs and
lymphatic nodes peritoneal cavity
Controls (n=15) 93% 20% 87% 93% 27%
TNF 20 (n=11) 46% 9% 91% 91% 36%
TNF 40 (n=5) 20% 40% 100% 60% 100%
TNF at a dose of 20 µg (TNF 20) or 40 µg (TNF 40) per injection was applied intratumorally. Control animals were injected with
vehicle.
Fig. 2. Acceleratory effect of rat TNF on the rate of appearance of
advanced tumor hemorrhagic necrosis. TNF at a dose of 20 µg per
injection was applied intratumorally to hamsters bearing Ab
melanoma. Control animals were injected with vehicle (see
Materials and Methods). Advanced hemorrhagic necrosis mani-
fested as perforation of tumor and a clot on its surface. Its appear-
ance was measured as the percentage of animals manifesting it for
all control and TNF-treated animals. The differences were statis-
tically significant between control animals (11 animals with
advanced necrosis from 17 animals) and animals injected with
TNF (13 from 13) after 10 days of intratumoral injections
(p=0.02). DTI – day of tumor implantation, DA – day of autopsy.Fig. 3. Effect of rat TNF and TNP-470 on
tumor tissues. Photographs show represen-
tative histological sections of the tumors
from 5 independent experiments (n=2 for
each group in each experiment) from: A –
control animals treated intratumorally and
subcutaneously with vehicle, B – animals
injected intratumorally with TNF at a dose
of 20 µg,  C – animals injected subcuta-
neously with TNP-470 at a dose of 30 mg/kg
of body weight, and D – animals injected
with TNF and TNP-470 (see Materials and
Methods). Microscope slides were pre-
pared from tumors 10 days after tumor
implantation. Excised sections of tumors
were fixed in formalin, embedded in paraf-
fin, and stained with a hematoxylin and
eosin. The arrows indicate areas of fibrosis
and accumulations of tumor cells with
nuclear pyknosis and karyorrhexis. b.v. –
blood vessel.
in those cultures, there were also mononuclear cells
infiltrating the tumor, such as lymphocytes and macro-
phages. Accordingly, the next two series of experiments
were performed to discover whether the TNF effect on
Ab cells in primary culture was direct and independent
of the presence of immunomodulatory cells.
The analysis aimed first at discovering whether there
were any changes in the cytotoxic effect of TNF on Ab
tumor cells in cultures enriched with lymphocytes or
macrophages isolated from the tumor-bearing animals
or from the healthy, non-tumor-bearing animals. A pos-
sible effect of TNF on lymphocytes or macrophages
could influence the cytotoxic effect on Ab melanoma
cells. Enrichment of the Ab tumor primary culture with
isolated splenocytes containing NK lymphocytes did not
change the dose-dependent cytotoxic effect of TNF on
Ab melanoma cells as measured by the /methyl-3H/-
-thymidine incorporation assay (Fig. 5). There was also
no change in the proliferation of the tumor cells as mea-
sured by the MTT proliferation assay (data not shown).
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Fig. 4. Dose-dependent cytotoxic effect of rat TNF on Ab tumor
cells in primary culture. The curve is an average of 8 independent
MTT tests. The mean deviations are marked. 
Fig. 5. Effect of enrichment of primary culture with splenocytes on
the cytotoxic effect of rat TNF on Ab tumor cells (ratio of Ab cells
to splenocytes: 1:5) as measured by the /methyl-3H/-thymidine
incorporation assay. Splenocytes were isolated from tumor-bear-
ing animals or from healthy, non tumor-bearing animals. The
/methyl-3H/-thymidine incorporation level by splenocytes alone
was stable at a level of 2000–3500 cpm and was not affected by
TNF concentration. As there was no difference between the
results concerning irradiated or non-irradiated splenocytes, only
the results concerning the former are shown. The graph shows the
average results of 8 independent tests.Since TNF did not affect the viability or the prolifera-
tion rate of splenocytes alone, the inhibitory effect of
TNF on the primary cell culture is probably indepen-
dent of lymphocyte-related mechanisms. 
Similar experiments were performed on Ab
melanoma cell cultures under conditions of enrich-
ment with peritoneal macrophages. Measurements of
Ab cells proliferation by the /methyl-3H/-thymidine
incorporation assay indicated that macrophages alone
inhibited the proliferation of the tumor cells. The addi-
tion of TNF into the cell culture enriched with peri-
toneal macrophages had no significant effect on the
proliferation of Ab melanoma cells (Fig. 6). As there
was no decrease in the viability of tumor cells in the
presence of macrophages alone as measured by the
MTT assay (data not shown), this suggests that
macrophages alone have a cytostatic effect on Ab
melanoma cells, probably through secreted TNF, and
thus diminish the cytotoxic effects of TNF added to the
cell culture. Since recombinant rat TNF did not affect
the viability or the proliferation rate of macrophages
alone, the inhibitory effect of rat TNF on the primary
cell culture is probably independent of macrophage-
-related mechanisms.
Further experiments involved DNA analysis of
tumor cells treated with TNF. DNA was isolated from
a one-week-old Ab cell culture after a 10-hour incuba-
tion with or without TNF. Such a culture is free of
macrophages and lymphocytes, so the effect of TNF on
the tumor cells should be direct. There was an increase
in the amount of low-molecular-weight DNA in iso-
lates from the cells incubated with TNF, as shown in
Fig. 7. Low-molecular-weight DNA seen as an apop-
totic ladder is an indication of apoptotic death of the
cells. An increase in the level of apoptotic death was
also detected by flow cytometry (data not shown). The
TNF cytotoxic effect on Ab melanoma cells in vitro is,
therefore, most probably exerted directly on tumor
cells through some enhancement of apoptotic cell
death. 
The influence of intratumoral injections of TNF 
on the activity of NK lymphocytes and macrophages
in vivo
In order to determine whether the anti-tumor activ-
ity of TNF in vivo is in part a result of its augmenting
effect on the natural cytotoxic activity of NK lympho-
cytes and/or macrophages, these cells were isolated
from healthy animals, tumor-bearing animals, and
tumor-bearing animals injected intratumorally with
TNF at a dose of 20 µg for 3 days from the moment the
tumor had become palpable. Subsequently, the cytotox-
ic activity of NK lymphocytes was measured by the 51Cr
release assay and the cytotoxic activity of the macro-
phages was measured by the /methyl-3H/-thymidine
incorporation assay with the K562 target cells. Figure 8
shows that the cytotoxic effect of NK lymphocytes was
dependent on their concentration and was not affected
by intratumoral application of TNF. Figure 9 shows, in
turn, that there was also no stimulation of natural cyto-
toxic activity of macrophages. These results indicate that
intratumoral injections of TNF did not significantly
stimulate the activity of peripheral immunomodulatory
cells in vivo.
The effect of TNF treatment 
on the cytokine concentration in the blood
The concentration of cytokines was measured in the
blood serum of healthy animals, tumor-bearing animals,
and tumor-bearing animals injected intratumorally with
TNF at a dose of 20 µg for three days from the moment
the tumor had become palpable. The results shown in
Fig. 10A indicate that intratumoral injections of TNF
did not significantly increase the amount of TNF in the
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Fig. 6. Effect of enrichment of primary culture with peritoneal
macrophages on the cytotoxic effect of rat TNF on Ab tumor cells
(ratio of Ab cells to macrophages: 1:2) as measured by the /methyl-
-3H/-thymidine incorporation assay. Peritoneal macrophages were
isolated from tumor-bearing animals or from healthy, non-tumor-
-bearing animals. The /methyl-3H/-thymidine incorporation level by
macrophages alone was stable and negligible at a level of 800–1000
cpm. The graph shows the average results of 8 independent tests.
Fig. 7. Increased apoptotic death of Ab melanoma tumor cells as
a result of TNF cytotoxic activity. The photographs of 1% agarose
gel show DNA isolated from one-week-old Ab cell cultures after
10 h incubation with or without TNF. Photograph A shows super-
natants with the low-molecular-weight DNA, photograph B shows
pellets with the high-molecular-weight DNA. Lanes: 1 – cells incu-
bated without TNF (control), 2 – cells incubated with TNF (1
µg/ml of culture medium). An increased amount of low-molecular-
weight DNA seen as an apoptotic ladder is visible on the gel lane
of the supernatant of low-molecular-weight DNA isolated from
the cells incubated with TNF.blood of tumor-bearing animals. However, there were
significant changes in the concentrations of cytokines
with IL-6 activity as a result of TNF treatment (Fig.
10B). The latter result suggests that the intratumoral
application of TNF affects in some manner the immune
system of Ab melanoma-bearing animals, possibly by
stimulating the acute-phase response.
DISCUSSION
Only a few kinds of melanoma tumors are common-
ly used to analyze the effects of TNF on the growth and
metastasis of melanoma. The most known is mouse B16
melanoma, a melanin-producing tumor which is highly
sensitive to TNF and its hypopigmenting activity [14].
This paper analyzes the mechanism of TNF action in
Bomirski (Ab) amelanotic melanoma and its usefulness
in studies of TNF as an anti-tumor agent. Ab melanoma
is a stable and widely studied tumor in our laboratory.
Some of its useful characteristics are: a high rate of
tumor growth, a high frequency and stability of metasta-
sis spread, and also some level of immunogenicity [8–11,
33, 45, 47]. 
By using recombinant rat TNF in a hamster model
we took advantage of the limited species specificity of
TNF [38, 58]. This was confirmed in our laboratory by
demonstrating a cytotoxic effect of rat TNF on the
human U937 and HeLa cell lines, mouse A9 cell line,
and later on hamster Ab melanoma cells ([33], data not
shown). TNF was applied intratumorally to subcuta-
neously implanted Ab melanoma in 3–10 doses from the
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Fig. 8. Cytotoxic activity of NK lymphocytes in vitro as measured
by the 51Cr release assay on K562 target cells. Splenocytes con-
taining NK lymphocytes were isolated from healthy animals
(spl.H), tumor-bearing animals (spl.Ab), and tumor-bearing ani-
mals injected intratumorally with TNF at a dose of 20 µg for 3 days
from the moment the tumor had become palpable (spl.AbTNF).
The ratios of effector to target cells were 5:1, 10:1, and 25:1 for
splenocytes from healthy animals and 25:1 for other splenocytes.
The graph shows the results of 3 independent experiments (n=2
for each group in each experiment). The mean deviations are
marked.
Fig. 9. Cytotoxic activity of macrophages in vitro as measured by
the /methyl-3H/-thymidine incorporation assay on K562 target
cells. Peritoneal macrophages were isolated from healthy animals
(m.H), tumor-bearing animals (m.Ab), and tumor-bearing animals
injected intratumorally with TNF at a dose of 20 µg for three days
from the moment the tumor had become palpable (m.AbTNF).
The ratios of effector to target cells were 0.1:1, 0.5:1, and 1:1 for
macrophages from healthy animals and 1:1 for other macro-
phages. The graph shows the results of 4 independent experiments
(n=2 for each group in each experiment). The mean deviations for
the 1:1 ratio are marked.
Fig. 10. Concentration of cytokines in the blood serum of healthy
animals (serum H), tumor-bearing animals (serum Ab), and
tumor-bearing animals injected intratumorally with TNF at a dose
of 20 µg for three days from the moment the tumor had become
palpable (serum AbTNF). Graph A shows the concentration of
TNF measured as the cytotoxic activity on the standard TNF-sen-
sitive A9 cell line. The standard curve was established using
human recombinant TNF (BASF Knoll AG, Germany). Graph
B shows the concentration of cytokines with the activity of IL-6
measured as a proproliferative effect on the IL-6-dependent B9
cell line. The standard curve was established using supernatant
from a murine splenocyte culture (48 h, RPMI with 5% FBS) with
an activity of 1000 U/ml. The results are from 5 independent
experiments (n=2 for each group in each experiment).moment the tumor had become palpable. We chose this
mode of application because of its lower toxicity at high
doses of TNF. Intratumoral application of TNF is used
in clinical applications, for example in the local treat-
ment of liver metastases [28, 31] and in the treatment of
advanced prostate cancer [36], with a significant anti-
-tumor effect and mild and transient toxic effects.
Additionally, in some experimental models, TNF
applied intratumorally or intravenously affected tumor
growth similarly, even with a stronger dependence of its
anti-tumor effect of intravenous application on the
immune system [21]. The chosen mode of TNF injection
also let us better evaluate the mechanism of TNF effect
on the growth and metastasis of Ab melanoma at the
early stage of its growth, before the development of
strong tumor vasculature (primary tumor up to 2–3 mm
in diameter). 
Having obtained evidence that TNF has a cytotoxic
effect not only on the TNF-sensitive A9 cell line, but
also on Ab melanoma cells in vitro, we found that the
intratumoral application of an immune modulator such
as TNF to hamsters bearing Ab melanoma resulted in
a significant inhibition of tumor growth. However, there
was only one case of complete regression caused by
treatment with very high doses of TNF, and the survival
time of the Ab melanoma-bearing hamsters did not dif-
fer from that of the control animals. TNF mostly
induced only a partial regression of tumors. The thera-
peutic effect of TNF was, therefore, weaker than in sim-
ilar mouse B16 melanoma, where a partial regression of
tumor was achieved by a single TNF injection. The anti-
-tumor effect of TNF was also much weaker than in the
case of mouse MethA sarcoma, where a single intratu-
moral injection of TNF caused a complete regression of
tumor [21] and in the case of mouse sarcoma 180, where
a few consecutive injections also led to complete cure
[32, 59]. In the former case, tumor cells were mostly
insensitive to TNF and there was a strong effect of TNF
on tumor vasculature, and in the latter case TNF was
toxic to aneuploid tumor cells without a visible effect on
tumor vessels. What was characteristic for both tumors
was their visible infiltration with immunomodulatory
cells. In yet another case of mouse sarcoma BP, where
there was no such infiltration and TNF exerted an influ-
ence mostly on tumor vasculature, there was no distinct
size reduction of the tumor [30, 59]. In experiments on
Ab melanoma, with inhibition of tumor growth by TNF,
there were also distinctive changes in the pattern of the
tumor metastasis. Such changes were associated by
other authors with changes induced by TNF in mouse
B16 melanoma in the expression of vascular cell adhe-
sion molecule 1 on endothelial cells [25, 52]. The fact
that in the Ab melanoma model TNF treatment signifi-
cantly decreased the incidence of kidney metastases in
a dose-dependent way but increased the frequency of
metastasis to the peritoneal cavity and the lungs shows
that this model can be useful in the analysis of the mech-
anism of action by which TNF modulates tumor metas-
tasis.
Since some differences were manifested in the me-
chanism of anti-tumor activity of TNF against different
melanomas, some analysis of the mode of TNF action
against Bomirski melanoma was performed. After a
3-day treatment of the tumor with TNF there were visi-
ble changes in tumor tissues similar to those in the
model of MethA sarcoma, with areas of fibrosis and
accumulations of tumor cells with nuclear pyknosis and
karyorrhexis, but there was no hyperemia of the vessels
[31]. Unlike in the model of MethA sarcoma, TNF had
a direct toxic effect on the tumor cells. It is documented
that TNF has a direct toxic effect on several neoplastic
cell lines [51, 63]. This effect can be cytostatic [65] or
cytotoxic through necrosis or apoptosis [17, 37]. For the
Ab melanoma tumor cells, the effect of TNF was cyto-
toxic, caused by an increase in apoptotic death, as docu-
mented by DNA analysis and flow cytometry. However,
the decrease in viability of the tumor cells during cyto-
toxic tests was not higher than 50% even with the high
doses of TNF. This may suggest that a cytostatic effect
of TNF is not to be excluded. Such a complex activity of
TNF can be seen, for example, in the case of MCF-7
human breast tumor, where TNF acts first as a cytostat-
ic agent on cultured tumor cells and then, after a long
period of cytostasis, as a strong cytotoxic agent [55].
However, for Ab tumor cells such a cytotoxic effect
could be seen much earlier, after only 10 h of incubation
with TNF. This could, therefore, suggest heterogeneity
of the Ab tumor cell population in view of its sensitivity
to TNF, similar to cases of human renal cell carcinoma
[23] or human colon cancer [43]. This can be supported
by our experiments with the Ab melanoma cell lines
derived from primary cell cultures that showed a low
sensitivity to the cytotoxic effect of TNF (data not
shown).
Besides the direct effect on tumor cells, TNF also
influenced the immune system of Ab melanoma hosts.
Its response to TNF was clearly indicated by an
increased concentration of cytokines with IL-6 activity
in blood serum, as in the cases of mouse B16 melanoma
[13]. As indicated in some earlier publications, at this
early stage of tumor growth, unlike later stages [8], there
was no stimulating effect of tumor presence alone on
the cytokine level. In this study we found that after
19–20 days of tumor growth there was an increase in 
IL-6 activity (50% of animals) and in the level of TNF
(90%) in the sera of untreated tumor-bearing hamsters,
and this correlated with the progression of cachexia.
A low concentration of TNF in blood serum at the early
stage of tumor development after TNF treatment,
therefore, indicated a low toxicity of such an application
of TNF. With no distinct toxic effect of TNF, there was
also no detectable increase in the natural cytotoxic activ-
ity of the immunomodulatory cells participating in
tumor control, such as NK cells. This contradicts the
fact that TNF stimulates in vitro the cytotoxicity of NK
cells towards many tumor cell lines [24, 54] and aug-
ments in vivo the activity of peritoneal NK cells [69].
However, TNF can also indirectly suppress the activity
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macrophages to produce prostaglandins [5, 56] and by
stimulating the expression of MHC I on tumor cells,
which results in a decrease in sensitivity to the anti-
-tumor activity of NK lymphocytes [67]. In the case of
mouse sarcoma 180 there was a similar lack of activation
of NK lymphocytes by intratumorally applied TNF [32],
and in the case of mouse fibrosarcoma CFS1, TNF
treatment even caused a decrease in the activity of
spleen NK lymphocytes [19, 39]. 
Along with NK cells, other immunomodulatory cells,
such as macrophages, also participate in tumor control.
Macrophages exert their cytotoxic activity on tumor
cells mostly by TNF secretion [15, 26] and NO2
– produc-
tion [26]. In Ab melanoma there was no detectable
increase in the natural cytotoxic activity of macrophages
in vivo by intratumorally injected TNF at this early stage
of tumor growth. But in vitro, in the primary tumor cell
culture enriched with peritoneal macrophages, there
was some, probably cytostatic, effect of macrophages
alone on tumor cells that was not modulated by adding
TNF into the medium. This in effect corroborates the
data from the literature which showed that macro-
phages exerted a cytostatic effect on tumor cells by
TNF-induced arrest in G1 phase of the cell cycle, which
can make them insensitive to TNF treatment [42]. The
absence of some increase in the activity of peritoneal
macrophages and spleen NK lymphocytes in the Ab
melanoma model does not exclude the possibility of
some local direct or indirect effect of TNF injection on
the activity of immunomodulatory cells in tumor tissues.
For example, TNF can increase the expressions of adhe-
sion molecules such as intercellular adhesion molecule 1
(ICAM-1) on tumor cells, thus increasing their vulnera-
bility to lysis by macrophages [71]. TNF can also upreg-
ulate ICAM-1 shedding from melanoma cells and thus
inhibit, by soluble ICAM-1, adherence of NK lympho-
cytes to tumor cells [6].
In the case of Ab melanoma it is also possible that
TNF treatment affected T lymphocytes since there was
a partial regression of tumor and even one complete
regression as an outcome of TNF application. As indi-
cated in the literature, tumor regression is entirely
dependent on T lymphocytes [4, 22, 50]. A suggested
mechanism of this process is that TNF activates Th lym-
phocytes which in turn activate cytotoxic T lymphocytes
(CTL) to destroy tumor cells [3]. Furthermore, some
recent experiments on knockout mice have indicated TNF
together with perforin and interferon γas a critical triad of
effector molecules in anti-tumor activity of CTL [57].
TNF has been also demonstrated to exert some effect
on tumor vessels. TNF is known to increase the perme-
ability of tumor vessels; this effect is stronger when TNF
is applied intratumorally and not intravenously [16].
TNF exerts its effect on tumor vessels by inducing apop-
tosis of endothelial cells in angiogenic tumor blood ves-
sels [60], by stimulating neutrophils to damage the
endothelium by proteolytic enzymes and toxic oxygen
intermediates [1, 66], and also by inducting procoagulant
activity of the endothelium, which results in tumor
ischemia [48, 49]. The effect of TNF on tumor blood ves-
sels in Ab melanoma was not visible at the early stage of
TNF application when only TNF was injected, but could
be seen in combined therapy with TNP-470. TNP-470 is
a hemisynthetic fumagillin analogue which not only
inhibits angiogenesis [7, 29], also in Ab melanoma [46,
47], but has a cytostatic and cytotoxic effect on endothe-
lial cells as well [27, 73]. TNF given in combination with
TNP-470 caused an increase in extravasation of erythro-
cytes compared with the effect of fumagillin analogue
used alone, and this suggests some effect of TNF on
tumor blood vessels. This idea is also supported by the
observation in this study that TNF treatment leads to
a statistically significant acceleration of advanced hem-
orrhagic necrosis of Ab melanoma primary tumor. 
At an early stage of tumor growth and with signifi-
cant differences in tumor size development between
TNF-treated and control animals, TNF application by
intratumoral injections did not visibly affect the activity
of immunomodulatory cells and the permeability of the
tumor blood vessels. Therefore, developmental differ-
ences were mainly the result of the direct anti-tumor
activity of TNF, as indicated in vivo by an increase in the
amount of tumor cells with nuclear pyknosis and karry-
orrhexis and its cytotoxic activity in vitro on the primary
culture of tumor cells. However, the effects of TNF
application visible at the later stage of tumor growth, as
for example accelerated hemorrhagic necrosis, may sug-
gest its influence on tumor vasculature and also, possi-
bly, its immunomodulatory effect. Therefore, hamster
Ab melanoma could be used as a model to analyze dif-
ferent aspects of the anti-tumor action of such a multi-
functional cytokine as TNF alone and in a combined
therapy. Additionally, this model can be used in studies
on the influence of TNF on metastasis of tumor cells.
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